Biocerna™ develops and commercializes non-invasive, readily accessible, easy-to-use and affordable diagnostics needed to accurately diagnose disease and support physicians in their prescribing practice.
Biocerna™ is a CAP-accredited and CLIA-approved laboratory, located in Fulton MD, in the heart of the MD scientific corridor and only few miles from the National Institute of Health (NIH) and the Food and Drug Administration (FDA).
Biocerna™ works also with medical products manufacturers to overcome some of the challenges of drug development by developing novel assays.
PGx360™ is a 22 markers, 62 genetic variation panel, designed to assist physicians in determining the most appropriate medications for their patients.
Biocerna™ offers the prioprietary DNA1 Advanced Alpha-1 ScreeningTM (DNA1), a new test that aims to improve diagnosis of Alpha-1 Antitrypsin Deficiency (Alpha-1)
Biocerna™ offers the prioprietary FHConfirm test, an innovative reflex-based test that aims to improve the diagnosis of Familial Hypercholesterolemia (FH).
Biocerna™ is in the process of assembling a suite of best-in-class oncology tests in our new pathology lab. Planning to launch in Fall 2018.